Kuvan: Phase IIIb started

BioMarin began a double-blind, placebo-controlled, international Phase IIIb trial to evaluate oral 20 mg/kg Kuvan given once daily for 13 weeks in about 200 patients ages 12 and up. BioMarin, which ma...